The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.

According to the 6 industry analysts covering Novavax, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$82m ...

Robert F. Kennedy Jr., President Donald Trump’s pick to head the US Department of Health and Human Services, was endorsed by ...

A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...

The bitter legal battle continues, with Baldoni launching a new website including texts and documents he says back his defense against Lively's sexual harassment claims. Josh Peck's wife of seven ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

HWGAX’s 3-year and 5-year annualized returns are 7% and 9%, respectively. HWGAX has a Zacks Mutual Fund Rank #1. Its net expense ratio is 1.20%. Hotchkis & Wiley Small Cap Value Fund invests the ...